Critical Appraisal of Reimbursement List in Bosnia and Herzegovina

Affiliations

¹ Regulatory Affairs Department, Alvogen Pharma d.o.o. Sarajevo, Bosnia and Herzegovina.
² Department of Social Pharmacy and Pharmaceutical Legislation, Faculty of Pharmacy, University of Belgrade Belgrade, Serbia.

Sabina Mujkic et al. Front Pharmacol. 2017.

. 2017 Mar 17:8:129.

doi: 10.3389/fphar.2017.00129. eCollection 2017.

¹ Regulatory Affairs Department, Alvogen Pharma d.o.o. Sarajevo, Bosnia and Herzegovina.
² Department of Social Pharmacy and Pharmaceutical Legislation, Faculty of Pharmacy, University of Belgrade Belgrade, Serbia.

No abstract available

Keywords: economic effects; health care system; legislation; price differences; reimbursement list.

Cited by

Medicine Availability and Prescribing Policy for Non-Communicable Diseases in the Western Balkan Countries.
Pekez-Pavlisko T, Racic M, Kusmuk S. Pekez-Pavlisko T, et al. Front Public Health. 2017 Nov 8;5:295. doi: 10.3389/fpubh.2017.00295. eCollection 2017. Front Public Health. 2017. PMID: 29167787 Free PMC article.
Population Perspectives on Impact of the COVID-19 Pandemic on Essential Health Services-Behavioral Insights from the Federation of Bosnia and Herzegovina.
Cilović-Lagarija Š, Musa S, Hasanica N, Čerkez G, Palo M, Majdan M, Scherzer M, Habersaat KB, Smallwood C, Tahirukaj A, Nitzan D. Cilović-Lagarija Š, et al. Behav Sci (Basel). 2022 Dec 3;12(12):495. doi: 10.3390/bs12120495. Behav Sci (Basel). 2022. PMID: 36546978 Free PMC article.
Pharmacoeconomic Analysis of Antiepileptic Reimbursement for Neuropathic Pain in Bosnia and Herzegovina - Budget Impact Analysis of Pregabalin.
Catic T, Jusufovic R, Tabakovic V. Catic T, et al. Mater Sociomed. 2018 Jun;30(2):89-94. doi: 10.5455/msm.2018.30.89-94. Mater Sociomed. 2018. PMID: 30061795 Free PMC article.
Physician Practice and Knowledge on Diabetes Management During Ramadan in Bosnia and Herzegovina.
Catic T, Jusufovic R. Catic T, et al. Mater Sociomed. 2020 Mar;32(1):57-61. doi: 10.5455/msm.2020.32.57-61. Mater Sociomed. 2020. PMID: 32410893 Free PMC article.

1. Cohen J. P., Stolk E., Niezen M. (2008). Role of budget impact in drug reimbursement decisions. J. Health Polit. Policy Law 33, 225–247. 10.1215/03616878-2007-054 - DOI - PubMed
1. Cohen J., Stolk E., Niezen M. (2007). The increasingly complex fourth hurdle for pharmaceuticals. Pharmacoeconomics 25, 727–734. 10.2165/00019053-200725090-00002 - DOI - PubMed
1. Drummond M., Jönsson B., Rutten F. (1997). The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 40, 199–215. 10.1016/S0168-8510(97)00901-9 - DOI - PubMed
1. Drummond M., Jönsson B., Rutten F., Stargardt T. (2010). Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. Eur. J. Health Econ. 12, 263–271. 10.1007/s10198-010-0274-y - DOI - PMC - PubMed
1. Forouzanfar M. H., Afshin A., Alexander L. T., Anderson H. R., Bhutta Z. A., Biryukov S., et al. . (2016). Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388, 1659–1724. 10.1016/S0140-6736(16)31679-8 - DOI - PMC - PubMed